Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
128.97
+1.67 (+1.31%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024
Via
MarketBeat
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
July 09, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
July 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
July 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
June 28, 2024
From
Merck & Co., Inc
Via
Business Wire
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
June 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
June 26, 2024
From
Daiichi Sankyo
Via
Business Wire
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
June 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
June 17, 2024
From
Merck & Co., Inc.
Via
Business Wire
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
June 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
June 17, 2024
From
Merck & Co., Inc.
Via
Business Wire
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
June 17, 2024
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA
Via
MarketBeat
Exposures
COVID-19
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Merck & Co., Inc.
Via
Business Wire
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage
June 03, 2024
Via
ACCESSWIRE
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
May 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck to Acquire EyeBio
May 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Third-Quarter 2024 Dividend
May 28, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
May 28, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
May 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
May 13, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
May 09, 2024
From
Merck & Co., Inc.
Via
Business Wire
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
May 08, 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
May 08, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
May 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
May 08, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
April 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces First-Quarter 2024 Financial Results
April 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
April 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
April 03, 2024
From
Daiichi Sankyo
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.